Premium Subscribers: Complete your KYC to Avoid
Service Suspension. Login Here.

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  
  • Home
  • Views On News
  • Feb 4, 2026 - 6 Stocks Across 6 Sectors to Watch Amid the India-US Trade Deal

6 Stocks Across 6 Sectors to Watch Amid the India-US Trade Deal

Feb 4, 2026

6 Stocks Across 6 Sectors to Watch Amid the India-US Trade DealImage source: Serhej Calka/www.istockphoto.com

The Indian stock market saw a euphoric rally after the India-US trade deal announcement on 3 January 2026.

India and the US unveiled a key trade agreement that brings immediate relief to Indian exporters, with US cutting reciprocal tariffs on Indian goods to 18% from 25%.

This comes after a tough phase when tariffs had surged to as high as 50%, hurting the competitiveness of Indian exports in the US and putting pressure on margins across export-driven sectors.

With tariffs now eased, companies with strong US exposure are likely to see better order visibility, margin expansion, and improved pricing power.

Against this backdrop, here are six stocks from six sectors to watch amid the India-US trade agreement.

  • Pharma

#1 Aurobindo Pharma

First on the list is Aurobindo Pharma.

Aurobindo Pharma is a multi-continent, multi-site pharmaceutical company with a widespread global manufacturing and export footprint.

Its diversified portfolio spans from APIs to finished formulation.

With operations catering to patients in over 150 countries across regulated and emerging markets, Aurobindo Pharma has established a strong global footprint.

It emerged as the third-largest Indian pharmaceutical company by revenue in FY25 and ranks among the top 10 generic pharmaceutical companies in eight European countries.

In the US, it holds the position of the largest generic pharma company by prescriptions dispensed.

As of FY25, the US remained Aurobindo Pharma's largest market, contributing 47% of total revenues.

Aurobindo Pharma

In Q2 FY26, US revenues grew 2% quarter-on-quarter and accounted for 43.9% of consolidated revenue, supported by strong growth in the base business despite lower transient product sales.

With the recent reduction in US tariffs on Indian goods, the company remains a key stock to watch, as improved pricing competitiveness, better order visibility and potential margin expansion could strengthen its growth outlook in its key export market.

Going forward, the company plans to accelerate post-2028 pipeline advancement with a focus on high-potential biosimilars.

For more details, see the AUROBINDO PHARMA company fact sheet and quarterly results.

Other Pharma Stocks to Watch

Company Revenue from US Market Period
Sun Pharma ~31% of total revenues FY25
Cipla ~21% of revenues (North America) Q3FY26
Gland Pharma ~52% of total revenues 9M FY26

Want To Read The Full Article?

Enter your email to continue reading on Equitymaster.

Important: We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
By submitting your email address, you also sign up for Profit Hunter, a daily newsletter from Equitymaster covering exciting investing ideas and opportunities in India.

Equitymaster requests your view! Post a comment on "6 Stocks Across 6 Sectors to Watch Amid the India-US Trade Deal". Click here!